Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?
Femminella GD, Livingston NR, Raza S, van der Doef T, Frangou E, Love S, Busza G, Calsolaro V, Carver S, Holmes C, Ritchie CW, Lawrence RM, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood B, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Passmore AP, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Tan T, Holscher C, Harrison J, Brooks DJ, Ballard C, Edison P. Femminella GD, et al. Among authors: nilforooshan r. Alzheimers Res Ther. 2021 Feb 17;13(1):47. doi: 10.1186/s13195-021-00784-w. Alzheimers Res Ther. 2021. PMID: 33597002 Free PMC article.
Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Among authors: nilforooshan r. Trials. 2019 Apr 3;20(1):191. doi: 10.1186/s13063-019-3259-x. Trials. 2019. PMID: 30944040 Free PMC article. Clinical Trial.
Minocycline at 2 Different Dosages vs Placebo for Patients With Mild Alzheimer Disease: A Randomized Clinical Trial.
Howard R, Zubko O, Bradley R, Harper E, Pank L, O'Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Nilforooshan R, Wilcock G, Gray R; Minocycline in Alzheimer Disease Efficacy (MADE) Trialist Group. Howard R, et al. Among authors: nilforooshan r. JAMA Neurol. 2020 Feb 1;77(2):164-174. doi: 10.1001/jamaneurol.2019.3762. JAMA Neurol. 2020. PMID: 31738372 Free PMC article. Clinical Trial.
Minocycline 200 mg or 400 mg versus placebo for mild Alzheimer’s disease: the MADE Phase II, three-arm RCT.
Howard R, Zubko O, Gray R, Bradley R, Harper E, Kelly L, Pank L, O’Brien J, Fox C, Tabet N, Livingston G, Bentham P, McShane R, Burns A, Ritchie C, Reeves S, Lovestone S, Ballard C, Noble W, Wilcock G, Nilforooshan R. Howard R, et al. Among authors: nilforooshan r. Southampton (UK): NIHR Journals Library; 2020 Apr. Southampton (UK): NIHR Journals Library; 2020 Apr. PMID: 32338849 Free Books & Documents. Review.
Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study).
Femminella GD, Frangou E, Love SB, Busza G, Holmes C, Ritchie C, Lawrence R, McFarlane B, Tadros G, Ridha BH, Bannister C, Walker Z, Archer H, Coulthard E, Underwood BR, Prasanna A, Koranteng P, Karim S, Junaid K, McGuinness B, Nilforooshan R, Macharouthu A, Donaldson A, Thacker S, Russell G, Malik N, Mate V, Knight L, Kshemendran S, Harrison J, Hölscher C, Brooks DJ, Passmore AP, Ballard C, Edison P. Femminella GD, et al. Among authors: nilforooshan r. Trials. 2020 Jul 19;21(1):660. doi: 10.1186/s13063-020-04608-4. Trials. 2020. PMID: 32684162 Free PMC article.
Perspectives and challenges in patient stratification in Alzheimer's disease.
Abdelnour C, Agosta F, Bozzali M, Fougère B, Iwata A, Nilforooshan R, Takada LT, Viñuela F, Traber M. Abdelnour C, et al. Among authors: nilforooshan r. Alzheimers Res Ther. 2022 Aug 13;14(1):112. doi: 10.1186/s13195-022-01055-y. Alzheimers Res Ther. 2022. PMID: 35964143 Free PMC article. Review.
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Swart AM, Telling T, Tabet N. Banerjee S, et al. Among authors: nilforooshan r. Health Technol Assess. 2023 Oct;27(23):1-108. doi: 10.3310/VPDT7105. Health Technol Assess. 2023. PMID: 37929672 Free PMC article. Clinical Trial.
Antipsychotic treatment of very late-onset schizophrenia-like psychosis (ATLAS): a randomised, controlled, double-blind trial.
Howard R, Cort E, Bradley R, Harper E, Kelly L, Bentham P, Ritchie C, Reeves S, Fawzi W, Livingston G, Sommerlad A, Oomman S, Nazir E, Nilforooshan R, Barber R, Fox C, Macharouthu AV, Ramachandra P, Pattan V, Sykes J, Curran V, Katona C, Dening T, Knapp M, Gray R; ATLAS Trialists Group. Howard R, et al. Among authors: nilforooshan r. Lancet Psychiatry. 2018 Jul;5(7):553-563. doi: 10.1016/S2215-0366(18)30141-X. Epub 2018 Jun 4. Lancet Psychiatry. 2018. PMID: 29880238 Free PMC article. Clinical Trial.
53 results